Regulatory Updates
Sep 5, 2026•1 min read
FDA Approves Sandoz DRALSERP Tablet (Hydralazine HCl/Reserpine) – ANDA084617
The FDA approved Sandoz's ANDA084617 for the oral tablet DRALSERP containing hydralazine hydrochloride 25 mg and reserpine 0.1 mg; the product is listed as discontinued.
Regulatory Updates
Aug 30, 2026•1 min read
TABLICAPS Submits ANDA085207 for Oral Reserpine 0.25 mg Tablet (Discontinued)
TABLICAPS has filed ANDA085207 for an oral 0.25 mg Reserpine tablet, which is listed with a discontinued marketing status.
Regulatory Updates
Aug 30, 2026•1 min read
FDA Approves ANDA083666 for Hydrochlorothiazide/Reserpine Oral Tablet
FDA has approved ANDA083666 submitted by Watson Labs for an oral tablet combining 50 mg hydrochlorothiazide and 0.125 mg reserpine; the product is listed as discontinued.
1